Rashida A Ferrand is an expert in Infectiology at Aga Khan University Hospital (Pakistan). As of October 2026, ScienceLeadR ranks Rashida A Ferrand in the top 1% of experts worldwide for Sexually Transmitted Diseases, HIV Infections and Immunologic Deficiency Syndromes. Rashida A Ferrand has authored 376 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 2 of them ongoing. SLR score: 1,632 (community average: 125). How the SLR is computed.

LeadR Profile

Rashida A Ferrand Aga Khan University Hospital Pakistan
1 632 ScienceLeadR Reputation 1632
Network Map

Infectiology

Subspecialties: Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2005 - 2026

Source: PubMed

London School of Hygiene & Tropical Medicine

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 376

Citations

Citations: 6 945 1st author: 28 Last author: 121 Unique author: 8


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Multimorbidity among older people in three African countries: a population-based cross-sectional study in The Gambia, South Africa, and Zimbabwe.
PMID 42933453 — quality of life, cross-sectional studies, blood, blood pressure, prevalence, multimorbidity, risk factors, healthy aging
Lancet Healthy Longev20260
Addressing the Geographic Reporting Bias in HIV-Associated Acquired Epidermodysplasia Verruciformis.
PMID 42902807 — bias, epidermodysplasia verruciformis, dermatology
Int J Dermatol20260
Unmet and Overlooked Needs of Pregnant Adolescents and Young Mothers in Zimbabwe: The Mixed-Methods "Kids With Kids" Study.
PMID 42836799 — pregnancy, mothers, parturition, adolescent, education
J Adolesc Health20260
HIVE MIND - Establishing globally relevant diagnostic criteria for HIV associated acquired epidermodysplasia verruciformis: an international Delphi study.
PMID 42723649 — skin, epidermodysplasia verruciformis, diagnosis
Wellcome Open Res20260
Multimorbidity and health-related quality of life after tuberculosis treatment in Zimbabwe: A cross-sectional study with household comparators.
PMID 42678960 — hypertension, quality of life, cross-sectional studies, lung, signs and symptoms, tuberculosis, multimorbidity, morbidity, therapeutics, lung diseases, memory, mental health
PLOS Glob Public Health20260

Clinical Studies 6

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 3
Phase 2/Phase 3 2
Phase 3 1

By status:

Completed 4
Active not recruiting 1
Recruiting 1

By type:

Interventional 6

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 3
multicentric5to9 0
multicentricup10 2

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
An Adolescent Health and Wellbeing Check up Programme in Three African Cities (Y Check)
NCT06090006 — depression, exercise, injections, oral health, research design, sexually transmitted diseases, malaria, hypertension, epilepsy, sexual behavior, circumcision, male, life style, immunization, healthy lifestyle, adolescent behavior, body mass index, hiv testing, safety, trichomonas infections, blood, eating, puberty, anemia, emergencies, pharmaceutical preparations, blood pressure, condoms, contraception, papilloma, adolescent development, hearing, contraceptives, oral, neisseria, diet, vaccination, employment, smartphone, adolescent, hiv, prehypertension, sexuality, viruses, health promotion, anxiety disorders, health facilities, folic acid, toothpastes, therapeutics, cities, diamines, overweight, history, sphygmomanometers, contraceptive agents, education, chlamydia, mental health, gonorrhea, suicide, human papillomavirus viruses, fluoride treatment
N/ARecruiting2023
DTG 3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to 15 Years Old
NCT04337450 — pharmaceutical preparations, lamivudine, tablets, nucleosides, rna-directed dna polymerase, maintenance, aged, hiv, peptide hydrolases, protease inhibitors, hiv infections, reverse transcriptase inhibitors, infections, child, integrases, dolutegravir
Phase 2/Phase 3Active not recruiting2022

LeadR Networks

Main global connection map